Abilify Maintena FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved February 28, 2013)
Brand name: Abilify Maintena
Generic name: aripiprazole
Dosage form: for Extended-Release Injectable Suspension
Company: Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
Treatment for: Schizophrenia, Bipolar Disorder
Abilify Maintena (aripiprazole) is an atypical antipsychotic indicated for the treatment of schizophrenia, and maintenance monotherapy treatment of bipolar I disorder.
Development timeline for Abilify Maintena
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.